Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT

This study is a prospective, multicenter randomized controlled trial (RCT) designed to compare the efficacy of segmentectomy and lobectomy for invasive lung adenocarcinoma with a diameter of 2-3 cm and intraoperative frozen section-confirmed IASLC pathological new grade 1-2. The non-inferiority of segmentectomy is primarily evaluated by 5-year relapse-free survival (RFS) and overall survival (OS) after surgery, while secondary endpoints include pulmonary function preservation, perioperative complications, etc. With a planned enrollment of 587 patients over a 3-year recruitment period and a 5-year follow-up, this study aims to identify an optimized surgical approach.

NCT Number	NCT07169903
Lead Sponsor	Shanghai Pulmonary Hospital, Shanghai, China Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine, Affiliated Hospital of Nantong University, Huadong Hospital, Anhui Chest Hospital, Ningbo No. 1 Hospital, Ningbo No.2 Hospital, Center hospital of Nanyang, The Affiliated Hospital of Xuzhou Medical University, Huzhou Central Hospital, Anhui Provincial Hospital, Shandong Public Health Clinical Center
Conditions	Lung Adenocarcinoma
Enrollment	587 participants
Start Date	2025-10-01
Primary Completion	2033-03-31 (estimated)
Study Completion	2033-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-12